STERIS plc（STE）の決算・業績分析
STERIS plcの2025年有価証券報告書をAI分析。売上高$5.5B(+6.2%)。営業利益$867M。Health Care。
目次
STERIS plcの2025年度 業績サマリー
STERIS plc（証券コード: STE）の2025年度決算・業績分析。売上高は$5.5B（前年比+6.2%）。営業利益は$867M（前年比+3.7%）。純利益は$615M（前年比+62.5%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
STERIS plcの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- Revenue surged 35.9% YoY to $4.2B (XBRL), driven by growth in consumable products and services.
- Net income declined 38.6% YoY to $244M (XBRL), despite strong operating cash flow of $685M (XBRL).
- Free cash flow reached $397M (XBRL), with $219M returned to shareholders via dividends and buybacks (XBRL).
- Gross margin remained robust at 44.6% (XBRL), but operating margin fell to 11.3% (XBRL), down 12.9% YoY.
STERIS plcの売上高変化の要因
- •Total revenue grew 35.9% YoY to $4.2B (XBRL), with a 5-year CAGR of 11.6% (XBRL). However, net income declined 38.6% YoY to $244M (XBRL), reflecting a 5-year CAGR of -18.1% (XBRL). Segment-specific revenue figures are not disclosed in the XBRL data or 10-K text (N/A). Growth is attributed to consumable products and services, though drivers are not quantified by segment (XBRL).
STERIS plcの営業利益変化の要因
- •Gross profit was $1.9B (XBRL) with a gross margin of 44.6% (XBRL). Operating income fell 12.9% YoY to $478M (XBRL), while net margin declined to 5.8% (XBRL). EBITDA was $1.0B (24.4% margin) (XBRL). Cost of sales changes and factors affecting operating profitability are not explicitly detailed in the data (XBRL).
STERIS plcの事業リスクと対応
International compliance risks due to conflicting laws and sanctions (10-K).
Adverse economic cycles affecting customer spending and credit availability (10-K).
Geopolitical instability (e.g., Russia-Ukraine conflict) causing supply chain and inflation risks (10-K).
Government healthcare funding cuts impacting customer payments (10-K).
Ongoing geopolitical risks exacerbating supply chain disruptions and financial volatility (10-K).
STERIS plcの事業内容
STERIS plc (STE) is a global provider of infection prevention products and services for healthcare, medical device, and pharmaceutical customers (10-K). The company generates revenue through consumable products (e.g., detergents, endoscopy accessories), capital equipment (e.g., sterilizers, surgical tables), and services (e.g., equipment maintenance, instrument repair, outsourced reprocessing) (10-K). Key segments include Healthcare (sterile processing, procedural solutions, capital equipment), Applied Sterilization Technologies (contract sterilization, lab testing, sterilization equipment), and Life Sciences (not detailed in text). Competitors include 3M, Baxter, Boston Scientific, Getinge, and Olympus (10-K). No single customer exceeded 10% of Healthcare segment revenue in FY2024 (10-K).
STERIS plcのAI業績分析レポート（2024年度）
Highlights
Business Overview
STERIS plc (STE) is a global provider of infection prevention products and services for healthcare, medical device, and pharmaceutical customers (10-K). The company generates revenue through consumable products (e.g., detergents, endoscopy accessories), capital equipment (e.g., sterilizers, surgical tables), and services (e.g., equipment maintenance, instrument repair, outsourced reprocessing) (10-K). Key segments include Healthcare (sterile processing, procedural solutions, capital equipment), Applied Sterilization Technologies (contract sterilization, lab testing, sterilization equipment), and Life Sciences (not detailed in text). Competitors include 3M, Baxter, Boston Scientific, Getinge, and Olympus (10-K). No single customer exceeded 10% of Healthcare segment revenue in FY2024 (10-K).
Revenue Analysis
Total revenue grew 35.9% YoY to $4.2B (XBRL), with a 5-year CAGR of 11.6% (XBRL). However, net income declined 38.6% YoY to $244M (XBRL), reflecting a 5-year CAGR of -18.1% (XBRL). Segment-specific revenue figures are not disclosed in the XBRL data or 10-K text (N/A). Growth is attributed to consumable products and services, though drivers are not quantified by segment (XBRL).
Profitability Analysis
Gross profit was $1.9B (XBRL) with a gross margin of 44.6% (XBRL). Operating income fell 12.9% YoY to $478M (XBRL), while net margin declined to 5.8% (XBRL). EBITDA was $1.0B (24.4% margin) (XBRL). Cost of sales changes and factors affecting operating profitability are not explicitly detailed in the data (XBRL).
Balance Sheet Analysis
Equity ratio was 56.2% (XBRL), with long-term debt of $3.0B (XBRL). Debt-to-equity (D/E) ratio was 0.78x (XBRL), and current ratio was 2.33x (XBRL). ROE was 4.0% (XBRL), ROA 2.2% (XBRL), and ROIC 2.9% (XBRL). No segment or geographic breakdown of assets or liabilities is provided (N/A).
Cash Flow Analysis
Operating cash flow was $685M (XBRL), with free cash flow of $397M (XBRL) after $288M in CapEx (XBRL). $163M in dividends and $56M in share repurchases were returned to shareholders (XBRL). CapEx intensity was 6.8% (XBRL), and R&D expense was $87M (XBRL).
Working Capital Analysis
Cash conversion cycle (CCC) was 128 days (XBRL), with receivables days at 75 days (XBRL), inventory days at 94 days (XBRL), and payables days at 41 days (XBRL).
Risks
Outlook
N/A (no forward-looking guidance or trends are explicitly mentioned in the XBRL data or 10-K text).
Health Careの企業一覧
STERIS plcと同じ「Health Care」セクターの企業